Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:approves |
1796
|
| gptkbp:availability |
limited to specific populations
|
| gptkbp:average_temperature |
-20° C
|
| gptkbp:booster_needed |
no booster needed after initial vaccination
|
| gptkbp:clinical_trial |
conducted for new formulations
|
| gptkbp:community_health |
important for bioterrorism preparedness
|
| gptkbp:community_impact |
eradicated smallpox in 1980
|
| gptkbp:contraindication |
pregnant women
immunocompromised individuals |
| gptkbp:contribution |
pioneered immunology field
|
| gptkbp:cultural_impact |
influenced modern vaccination practices
|
| gptkbp:developed_by |
gptkb:Edward_Jenner_Jr.
|
| gptkbp:distribution |
distributed during outbreaks
|
| gptkbp:historical_significance |
first successful vaccine
|
| gptkbp:historical_use |
gptkb:military_personnel
healthcare workers laboratory workers handling variola virus |
| gptkbp:history |
developed from cowpox virus
|
| https://www.w3.org/2000/01/rdf-schema#label |
Smallpox vaccine
|
| gptkbp:invention |
originally patented by Edward Jenner
|
| gptkbp:is_effective_against |
95% effective
|
| gptkbp:is_recommended_for |
high-risk populations
|
| gptkbp:is_vulnerable_to |
studies on long-term immunity
live virus vaccine high efficacy in preventing disease historical skepticism about vaccination important for public health education issues with vaccine distribution led to development of other vaccines part of the history of vaccination significantly reduced smallpox cases globally single dose recommended for adults two doses recommended for children |
| gptkbp:legacy |
considered a major public health achievement
|
| gptkbp:manufacturer |
various pharmaceutical companies
|
| gptkbp:produced_by |
vaccinia virus
|
| gptkbp:public_awareness |
campaigns for vaccination in the past
|
| gptkbp:replaced_by |
vaccinia virus vaccine
|
| gptkbp:research |
ongoing studies on safety and efficacy
|
| gptkbp:research_focus |
improving vaccine delivery methods
|
| gptkbp:rounds |
smallpox disease
|
| gptkbp:route_of_administration |
subcutaneous injection
|
| gptkbp:safety_measures |
ongoing safety assessments
|
| gptkbp:scientific_classification |
endorsed use
|
| gptkbp:side_effect |
skin rash
mild fever injection site reaction |
| gptkbp:supply_chain |
managed by health organizations
|
| gptkbp:type |
live attenuated virus vaccine
|
| gptkbp:used_for |
smallpox prevention
|
| gptkbp:vaccine_policy |
part of global vaccination policies
|
| gptkbp:vaccine_regulation |
regulated by health authorities
|
| gptkbp:vaccine_success |
considered a model for future vaccines
|
| gptkbp:bfsParent |
gptkb:Edward_Jenner_Jr.
|
| gptkbp:bfsLayer |
6
|